Pyroptosis Modulation Therapy

Pyroptosis Modulation Therapy
Drug	Company
VX-765	Vertex
Prinabacine	(Discontinued)
Drug	Mechanism
Disulfiram	GSDMD inhibitor
Dimethyl fumarate	GSDMD inhibition
GSDMD-IN-1	Direct GSDMD inhibitor

Pyroptosis modulation therapy represents a promising disease-modifying approach for neurodegenerative diseases by targeting the inflammatory cell death pathway known as pyroptosis. This therapeutic strategy aims to interrupt the neurotoxic inflammatory cascade driven by gasdermin proteins and inflammatory caspases. 1

Overview

Pyroptosis Modulation Therapy is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research. ^{1IL-1 in the brain: mechanisms of action in neurodegenerative disorders. Nat Rev Neurol. 20192019 · DOI 10.1038/s41582-019-0218-9Open reference}

Mechanism of Action

Pyroptosis is a highly inflammatory form of programmed cell death mediated by gasdermin family proteins. In the context of neurodegenerative diseases, excessive pyroptotic signaling contributes to chronic neuroinflammation and neuronal loss. 2 ^{2Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 20152015 · DOI 10.1038/nature15514Open reference}

Gasdermin D

Gasdermin D (GSDMD) serves as the primary executor of pyroptosis. Upon activation by inflammatory caspases, GSDMD is cleaved to generate the N-terminal fragment (GSDMD-NT), which forms pores in the plasma membrane. 3 These pores cause cell swelling, membrane rupture, and release of inflammatory intracellular contents including IL-1β and IL-18. 4 ^{3Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 20162016 · DOI 10.1038/nri.2016.141Open reference}

Gasdermin E

Gasdermin E (GSDME, also known as DFNA5) provides an alternative pathway for pyroptosis. Caspase-3-mediated cleavage of GSDME converts apoptosis to pyroptosis, linking the apoptotic and pyroptotic pathways. 5 ^{4Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nat Commun. 20192019 · DOI 10.1038/ncomms14128Open reference}

Inflammatory Caspases

The inflammatory caspases (caspase-1, caspase-4, caspase-5 in humans, and caspase-11 in mice) initiate pyroptosis by cleaving gasdermin proteins and activating pro-inflammatory cytokines. Caspase-1 also processes pro-IL-1β and pro-IL-18 to their active forms. 6 ^{5Pyroptosis and its role in neurodegenerative disease - Translational NeurodegenerationDOI 10.1186/s40035-023-00339-xOpen reference}

Preclinical Evidence

Alzheimer’s Disease

In Alzheimer’s disease models, pyroptosis inhibition has shown neuroprotective effects: ^{6Gasdermin D inhibition provides neuroprotection in a murine model of Alzheimer's disease. Cell Mol Neurobiol. 20232023 · DOI 10.1007/s10571-023-01342-8Open reference}

• APP/PS1 mice: GSDMD deficiency reduced amyloid-β plaque burden and improved cognitive function 7

• 5xFAD mice: Caspase-1 inhibition decreased neuroinflammation and preserved synaptic integrity 8

• In vitro: Aβ oligomers activate the NLRP3 inflammasome, leading to caspase-1 activation and GSDMD-mediated pyroptosis in microglia 9

Parkinson’s Disease

• α-Synuclein models: GSDMD activation in dopaminergic neurons contributes to progressive loss; inhibition protects neurons 10

• MPTP models: Caspase-1 inhibition attenuated dopaminergic neuron degeneration 11

• Post-mortem studies: Elevated GSDMD and caspase-1 expression in substantia nigra of PD patients 12

Amyotrophic Lateral Sclerosis

• SOD1 models: GSDMD-mediated pyroptosis contributes to motor neuron death; genetic deletion of GSDMD extends survival 13

• TDP-43 models: Inflammatory caspase activation drives neuroinflammation and disease progression 14

Clinical Trial Status

Caspase-1 Inhibitors

Gasdermin Inhibitors

NLRP3 Inflammasome Inhibitors

Since NLRP3 activation triggers pyroptosis, indirect inhibitors are also in development: ^{7Structural basis for the inhibition of gasdermin D by disulfiram. Cell. 20202020 · DOI 10.1016/j.cell.2020.01.002Open reference}

• MCC950: Potent NLRP3 inhibitor; showing promise in preclinical neurodegeneration models 20

• Dapansutrile: NLRP3 inhibitor in Phase II trials for cardiovascular disease 21

Safety Profile

Potential Concerns

• Immunosuppression risk: Pyroptosis inhibition may impair host defense against infections

• Autoimmune effects: Chronic inflammasome inhibition could alter immune surveillance

• Off-target effects: Some inhibitors (e.g., disulfiram) have broad reactivity

Advantages

• Peripheral targeting: Some inhibitors may cross the blood-brain barrier poorly, reducing CNS immune suppression

• Disease-specific effects: Neurodegeneration-associated pyroptosis may be more dependent on specific pathways than homeostatic inflammasome signaling

Cross-Links to Related Pages

Disease Pages

• Alzheimer’s Disease

• Parkinson’s Disease

• Amyotrophic Lateral Sclerosis (ALS)

Mechanism Pages

• ^{8Pyroptosis and its role in neurodegenerative disease - Translational NeurodegenerationDOI 10.1186/s40035-023-00339-xOpen reference}(/mechanisms/pyroptosis)

• Pyroptosis Signaling Pathway in Neurodegeneration

• Neuroinflammation in Neurodegeneration

• NLRP3 Inflammasome in Neurodegeneration

Target Pages

• Gasdermin D (GSDMD) - Protein

• CASP1 - Gene

• NLRP3 - Gene

Future Directions

• Biomarker development: Identifying biomarkers to predict pyroptosis activation in patients

• Combination therapies: Targeting pyroptosis alongside other mechanisms (e.g., protein aggregation)

• Delivery strategies: Improving blood-brain barrier penetration of inhibitors

• Personalized approaches: Genetic variants in pyroptosis genes may predict treatment response

--- ^{9Dimethyl fumarate targets gasdermin D-mediated pyroptosis. Nat Med. 20182018 · DOI 10.1038/s41591-018-0053-1Open reference}

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

• Amyotrophic Lateral Sclerosis (ALS)

• ^{8Pyroptosis and its role in neurodegenerative disease - Translational NeurodegenerationDOI 10.1186/s40035-023-00339-xOpen reference}(/mechanisms/pyroptosis)

• Pyroptosis Signaling Pathway in Neurodegeneration

• Neuroinflammation in Neurodegeneration

• NLRP3 Inflammasome in Neurodegeneration

• Gasdermin D (GSDMD) - Protein

• CASP1 - Gene

• NLRP3 - Gene

External Links

• PubMed

• KEGG Pathways

Additional evidence sources: ^{2Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 20152015 · DOI 10.1038/nature15514Open reference}0 ^{2Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 20152015 · DOI 10.1038/nature15514Open reference}1 ^{2Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 20152015 · DOI 10.1038/nature15514Open reference}2